Zobrazeno 1 - 10
of 22
pro vyhledávání: '"Nicole, Feller"'
Autor:
Corine J. Hess, Nicole Feller, Fedor Denkers, Angèle Kelder, Pauline A. Merle, Michael C. Heinrich, Amy Harlow, Johannes Berkhof, Gert J. Ossenkoppele, Quinten Waisfisz, Gerrit J. Schuurhuis
Publikováno v:
Haematologica, Vol 94, Iss 1 (2009)
Background About 70–80 percent of patients with acute myeloid leukemia enter complete remission, but at least half of these patients who achieve remission go on to relapse. Improved treatment is likely to come from increasing the time to relapse, e
Externí odkaz:
https://doaj.org/article/000a5dbd77e8473c871c7c8c45cc02f0
Autor:
Anna van Rhenen, Nicole Feller, Gerrit Jan Schuurhuis, Sonja Zweegman, Gert J. Ossenkoppele, Monique Terwijn, Guus Westra, Angèle Kelder
Publikováno v:
Terwijn, M, Feller, N, van Rhenen, A, Kelder, A, Westra, G A, Zweegman, S, Ossenkoppele, G J & Schuurhuis, G J 2009, ' Interleukin-2 receptor alpha-chain (CD25) expression on leukaemic blasts is predictive for outcome and level of residual disease in AML ', European Journal of Cancer, vol. 45, no. 9, pp. 1692-1699 . https://doi.org/10.1016/j.ejca.2009.02.021
European Journal of Cancer, 45(9), 1692-1699. Pergamon
European Journal of Cancer, 45(9), 1692-1699. Pergamon
We investigated the role of CD25 as a prognostic marker in acute myeloid leukaemia (AML). Seventy-two newly diagnosed patients ≤60 years were retrospectively analysed by flow cytometry for CD25 positivity of AML blasts. Patients with CD25 expressio
Autor:
Peter C. Huijgens, M A van der Pol, Nicole Feller, A van Stijn, Gert J. Ossenkoppele, Gerrit-Jan Schuurhuis, G W D Weijers, Guus Westra
Publikováno v:
Leukemia. 17:68-75
In this study, a high CD34% in autologous peripheral blood stem cell (PBSC) products from 71 AML patients was associated directly with a high relapse rate (P = 0.006) and inversely with disease-free survival (P = 0.003), irrespective whether patients
Autor:
Rik A. Brooimans, Nicole Feller, Jan-Willem Gratama, H Wind, I. de Greef, Gerrit-Jan Schuurhuis, V H J van der Velden, Patrik Aerts, Angèle Kelder, Nancy Boeckx, M. Leenders, J. G te Marvelde, Frank Preijers, Guus Westra
Publikováno v:
Blood Cancer Journal, 3, pp. e129
Blood Cancer Journal
Feller, N, van der Velden, V H J, Brooimans, R A, Boeckx, N, Preijers, F, Kelder, A, de Greef, I, Westra, G, te Marvelde, J G, Aerts, P, Wind, H, Leenders, M, Gratama, J W & Schuurhuis, G J 2013, ' Defining consensus leukemia-associated immunophenotypes for detection of minimal residual disease in acute myeloid leukemia in a multicenter setting ', Blood cancer journal, vol. 3, e129 . https://doi.org/10.1038/bcj.2013.27
Blood Cancer Journal, 3, e129
Blood cancer journal, 3:e129. Nature Publishing Group
Blood Cancer Journal, 3. Nature Publishing Group
Blood Cancer Journal
Feller, N, van der Velden, V H J, Brooimans, R A, Boeckx, N, Preijers, F, Kelder, A, de Greef, I, Westra, G, te Marvelde, J G, Aerts, P, Wind, H, Leenders, M, Gratama, J W & Schuurhuis, G J 2013, ' Defining consensus leukemia-associated immunophenotypes for detection of minimal residual disease in acute myeloid leukemia in a multicenter setting ', Blood cancer journal, vol. 3, e129 . https://doi.org/10.1038/bcj.2013.27
Blood Cancer Journal, 3, e129
Blood cancer journal, 3:e129. Nature Publishing Group
Blood Cancer Journal, 3. Nature Publishing Group
Contains fulltext : 186455.pdf (Publisher’s version ) (Open Access) Flow-cytometric detection of minimal residual disease (MRD) has proven in several single-institute studies to have an independent prognostic impact. We studied whether this relativ
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3f88cada1faa950de5a787ab4c72389e
https://hdl.handle.net/2066/186455
https://hdl.handle.net/2066/186455
Autor:
Henk J. Broxterman, Carolien H. M. Versantvoort, Herbert M. Pinedo, Jan Lankelma, Nicole feller
Publikováno v:
Biochemical Pharmacology. 48:1129-1136
In several multidrug resistant tumor cell lines without overexpression of P-glycoprotein (non-Pgp MDR), a decreased accumulation of drugs has been shown to contribute to resistance. We have recently reported that daunorubicin (DNR) accumulation was d
Autor:
Rob F M, Bevers, Jan J, Battermann, Jourik A, Gietema, Christina A, Hulsbergen-Van de Kaa, Theo M, de Reijke, Nicole, Feller, J A Fred, Witjes
Publikováno v:
Nederlands tijdschrift voor geneeskunde. 153
Urothelial carcinoma of the bladder is diagnosed predominantly in people over 60 years of age. The most common symptom is haematuria. Smoking is an important risk factor (relative risk 2.5 to 3). Cystoscopy is performed whenever bladder carcinoma is
Publikováno v:
Feller, N, Kelder, A, Westra, G A, Ossenkoppele, G J & Schuurhuis, G J 2008, ' Positive selection for CD90 as a purging option in acute myeloid leukemia stem cell transplants ', Cytometry Part B. Clinical Cytometry, vol. 74, no. 1, pp. 9-16 . https://doi.org/10.1002/cyto.b.20375
Cytometry Part B. Clinical Cytometry, 74(1), 9-16. Wiley-Liss Inc.
Cytometry Part B. Clinical Cytometry, 74(1), 9-16. Wiley-Liss Inc.
Background: Several studies showed the benefit of purging of acute myeloid leukemia (AML) stem cell transplants. We reported previously that purging by positive selection of CD34+ and CD133+ cells resulted in a 3–4 log tumor cell reduction (TCR) in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::65566679db28a6bbef5e93fbf4ddb981
https://research.vumc.nl/en/publications/f069f885-bd75-4e21-9302-8ae10a287275
https://research.vumc.nl/en/publications/f069f885-bd75-4e21-9302-8ae10a287275
Autor:
Nicole Feller, A W M Nieuwint, Gerrit-Jan Schuurhuis, Bijan Moshaver, Sonja Zweegman, Angèle Kelder, A. van Rhenen, Gert J. Ossenkoppele
Publikováno v:
Leukemia. 21(8)
Acute myeloid leukemia (AML) is generally regarded as a stem cell disease. In CD34-positive AML, the leukemic stem cell has been recognized as CD38 negative. This CD34+CD38- population survives chemotherapy and is most probable the cause of minimal r
Autor:
Fedor Denkers, Gerrit Jan Schuurhuis, Nicole Feller, Pauline A. Merle, Quinten Waisfisz, Corine J. Hess, Gert J. Ossenkoppele
Publikováno v:
Blood, 106(11), 162A-162A. American Society of Hematology
Hess, CJ, Feller, N, Denkers, F, Merle, PA, Ossenkoppele, GJ, Waisfisz, Q & Schuurhuis, GJ 2005, ' Immunophenotypical minimal residual disease as a short term endpoint for monitoring effects of targeted inhibitors in acute myeloid leukemia. ', Blood, vol. 106, no. 11, pp. 162A-162A . https://doi.org/10.1182/blood.V106.11.545.545
Hess, CJ, Feller, N, Denkers, F, Merle, PA, Ossenkoppele, GJ, Waisfisz, Q & Schuurhuis, GJ 2005, ' Immunophenotypical minimal residual disease as a short term endpoint for monitoring effects of targeted inhibitors in acute myeloid leukemia. ', Blood, vol. 106, no. 11, pp. 162A-162A . https://doi.org/10.1182/blood.V106.11.545.545
At present, a large number of clinical trails make use of inhibitors that target leukemia specific defects, such as BCR-ABL, c-kit mutations or tandem duplications in the FLT3 gene (FLT3-ITD). Irrespective of their target, these studies all share the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::639599267d06f28498153f31cf5004eb
https://research.vumc.nl/en/publications/ff587fdc-0ddb-450c-96f5-3f6169307452
https://research.vumc.nl/en/publications/ff587fdc-0ddb-450c-96f5-3f6169307452
Autor:
Alexander B H, Bakker, Sonja, van den Oudenrijn, Arjen Q, Bakker, Nicole, Feller, Marja, van Meijer, Judith A, Bia, Mandy A C, Jongeneelen, Therese J, Visser, Nora, Bijl, Cecilia A W, Geuijen, Wilfred E, Marissen, Katarina, Radosevic, Mark, Throsby, Gerrit Jan, Schuurhuis, Gert J, Ossenkoppele, John, de Kruif, Jaap, Goudsmit, Ada M, Kruisbeek
Publikováno v:
Cancer research. 64(22)
Acute myeloid leukemia (AML) has a poor prognosis due to treatment-resistant relapses. A humanized anti-CD33 antibody (Mylotarg) showed a limited response rate in relapsed AML. To discover novel AML antibody targets, we selected a panel of single cha